The Operating Theatre Journal - Flipbook - Page 8
Ciliatech releases new design of glaucoma surgical
device CID, following patent reinforcement
Second-generation CID (Cilioscleral Interpositioning Device) makes cilioscleral surgical procedure, which leaves anterior chamber of eye
untouched, less invasive and easier to perform
Ciliatech,
an
ophthalmology
medtech
company developing a new class of implant to
treat glaucoma durably, today announces the
release of a new design of its CID (Cilioscleral
Interpositioning Device), following the 昀椀ling
of additional patents strengthening its IP
(Intellectual Property). CID is the unique
glaucoma surgical device used in the cilioscleral
technique to lower IOP (intraocular pressure)
while preserving the anterior chamber of the
eye, which in turn avoids serious medical
complications, notably Endothelial Cell Loss
(ECL) or a 昀椀ltration bleb. The cilioscleral
technique is also unique in its ability to treat
the two main types of glaucoma: open angle
or angle-closure (narrow angle).
The new patents protect modi昀椀cations in the
shape and geometry of CID, principally to
further improve its perfomance and safety.
This second-generation CID, currently in
clinical trials, makes the cilioscleral technique
less invasive and traumatic to the eye; the
conjunctiva is better protected, and incisions
are smaller.
“We are highly satis昀椀ed with the performance
of our second-generation of CID. We redesigned
it to provide an unequaled safety pro昀椀le, and
enhanced IOP reduction and maintenance,
without medication over time,” said Philippe
Sourdille, co-founder of Ciliatech and inventor
of CID.
“The new CID improves the very positive results
we already achieved with our 昀椀rst-generation
device across all aspects: performance, safety,
surgical technique and post-op medication.
This shows that Ciliatech has progressed in
understanding the key underlying mechanisms
monitoring aqueous humor circulation. We
are identifying important parameters that
leverage clinical outcomes.
8
This is the CID design we will 昀椀le for CE
marking and will introduce to the market in
2025.”
Ciliatech secured patents on substantial
revisions to the shape of the CID implant to
improve both the water collection from the
anterior chamber and its circulation down to
drainage channels. The overall size was also
slightly modi昀椀ed to allow smaller incisions
and further reduce the invasiveness of the
procedure.
CID offers strong IOP reduction
Preliminary results in a 12-month clinical
study (SAFARI III) of 57 patients 昀椀tted with
the new design have shown that this secondgeneration CID tends to deliver better IOP
control, 13.9mmHg compared to 15.1mmHg in
earlier studies (SAFARI I & II) using the 昀椀rstgeneration model. Ciliatech says that this is
signi昀椀cant, particularly when post-op IOPs
are already in the low teens. In the SAFARI III
12-month results, more than 85% of patients
reported being medication free.
For surgeons, this new model makes the
cilioscleral procedure quicker (less than
15 minutes) and easier to perform, further
reducing the learning curve. CID can be used
similarly to a MIGS (Minimally Invasiveness
Glaucoma Surgery) device in patients with
open angle glaucoma. Unlike MIGS, it can be
used to treat primary angle closure glaucoma,
where patients have a two-fold greater risk of
vision loss during their lifetime, without the
need to remove the lens.
“With stronger IOP reduction, this secondgeneration CID may also be bene昀椀cial for more
advanced glaucoma cases, helping a larger
number of patients to postpone the need for
traditional incisional approaches,” said Olivier
Benoit, CEO of Ciliatech.
THE OPERATING THEATRE JOURNAL
About CID (Cilioscleral Interpositioning
Device)
Ciliatech’s CID is a non-resorbable implant
which remains in place for the patient’s
lifetime. It is a single piece of 26% hydrophilic
acrylic, a raw material widely used in the
manufacturing of intra-ocular lenses, which
ensures long-term biocompatibility.
The device consists of a speci昀椀cally designed
6mm large, 3.5mm wide and 500µm thick
plate. The anterior edge contains several
contact points aimed at adapting to the
natural variation of patient-to-patient iris
diameter.
The face, in regard to the ciliary body, is
smooth, to avoid traumas, while the one
facing the sclera is designed to maximize the
aqueous circulation to the choroid and the
sclera-conjunctival vessels.
How CID is applied
In a CID procedure, the surgeon only needs
to make two full thickness scleral incisions,
then pull the device below the sclera and
following that, suture tight the incisions to
avoid conjunctival 昀椀ltration. The conjunctiva
is spared. It is only incised locally, on top of
the scleral incisions.
Further information: www.cilia.tech
www.otjonline.com